18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons
暂无分享,去创建一个
Clifford R. Jack | Jeffrey L. Gunter | Prashanthi Vemuri | Matthew L. Senjem | Ronald C. Petersen | Stephen D. Weigand | Val J. Lowe | David S. Knopman | Bradley F. Boeve | Kejal Kantarci | Michelle M. Mielke | Heather J. Wiste | C. Jack | J. Gunter | R. Petersen | B. Boeve | P. Vemuri | M. Senjem | D. Knopman | V. Lowe | K. Kantarci | H. Wiste | S. Weigand | R. Roberts | M. Mielke | Rosebud O. Roberts | E. Lundt | Emily S. Lundt | D. Knopman | R. Roberts
[1] J. Morris,et al. Functional deactivations: Change with age and dementia of the Alzheimer type , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[2] C. Jack,et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.
[3] Jennifer L. Whitwell,et al. Hippocampal volumes, proton magnetic resonance spectroscopy metabolites, and cerebrovascular disease in mild cognitive impairment subtypes. , 2008, Archives of neurology.
[4] P. Matthews,et al. Distinct patterns of brain activity in young carriers of the APOE e4 allele , 2009, NeuroImage.
[5] Elizabeth C Mormino,et al. Not quite PIB-positive, not quite PIB-negative: Slight PIB elevations in elderly normal control subjects are biologically relevant , 2012, NeuroImage.
[6] Bedda L. Rosario,et al. Basal Cerebral Metabolism May Modulate the Cognitive Effects of Aβ in Mild Cognitive Impairment: An Example of Brain Reserve , 2009, The Journal of Neuroscience.
[7] Sirkka Goebeler,et al. Apolipoprotein E–dependent accumulation of Alzheimer disease–related lesions begins in middle age , 2009, Annals of neurology.
[8] G. Alexander,et al. Declining brain activity in cognitively normal apolipoprotein E ɛ4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[9] W. Jagust,et al. Apolipoprotein E, Not Fibrillar β-Amyloid, Reduces Cerebral Glucose Metabolism in Normal Aging , 2012, The Journal of Neuroscience.
[10] Cindee M. Madison,et al. Covarying alterations in Aβ deposition, glucose metabolism, and gray matter volume in cognitively normal elderly , 2014, Human brain mapping.
[11] J. Hodges,et al. Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment , 2003, Annals of neurology.
[12] C R Jack,et al. Effects of Age on the Glucose Metabolic Changes in Mild Cognitive Impairment , 2010, American Journal of Neuroradiology.
[13] Suzanne E. Welcome,et al. Mapping cortical change across the human life span , 2003, Nature Neuroscience.
[14] N. Foster,et al. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease , 1997, Annals of neurology.
[15] C. Jack,et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. , 2008, Brain : a journal of neurology.
[16] Naruhiko Sahara,et al. Propagation of Tau Pathology in a Model of Early Alzheimer's Disease , 2012, Neuron.
[17] A. Dale,et al. Brain Changes in Older Adults at Very Low Risk for Alzheimer's Disease , 2013, The Journal of Neuroscience.
[18] C. Jack,et al. FLAIR histogram segmentation for measurement of leukoaraiosis volume , 2001, Journal of magnetic resonance imaging : JMRI.
[19] M N Cantwell,et al. Does cerebral blood flow decline in healthy aging? A PET study with partial-volume correction. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[20] Jeffrey A. James,et al. Amyloid imaging in mild cognitive impairment subtypes , 2009, Annals of neurology.
[21] A. Fagan,et al. APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging , 2010, Annals of neurology.
[22] L. Mosconi,et al. Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[23] S. DeKosky,et al. Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[24] A. Alavi,et al. Regional cerebral glucose metabolism in healthy volunteers determined by fluordeoxyglucose positron emission tomography: appearance and variance in the transaxial, coronal, and sagittal planes. , 2000, Clinical nuclear medicine.
[25] C. Rowe,et al. Imaging β-amyloid burden in aging and dementia , 2007, Neurology.
[26] A. Alavi,et al. Regional cerebral function determined by FDG-PET in healthy volunteers: normal patterns and changes with age. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[27] Jean-Marc Constans,et al. Voxel-based mapping of brain gray matter volume and glucose metabolism profiles in normal aging , 2009, Neurobiology of Aging.
[28] et al.,et al. Discrimination between Alzheimer Dementia and Controls by Automated Analysis of Multicenter FDG PET , 2002, NeuroImage.
[29] V. Pankratz,et al. The Mayo Clinic Study of Aging: Design and Sampling, Participation, Baseline Measures and Sample Characteristics , 2008, Neuroepidemiology.
[30] D. Schacter,et al. The Brain's Default Network , 2008, Annals of the New York Academy of Sciences.
[31] J. Gunter,et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease , 2012, Neurology.
[32] C. Jack,et al. An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease , 2012, Annals of neurology.
[33] Norbert Schuff,et al. Measurement of MRI scanner performance with the ADNI phantom. , 2009, Medical physics.
[34] M. Mintun,et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline , 2012, Annals of neurology.
[35] E G Tangalos,et al. The incidence of MCI differs by subtype and is higher in men , 2012, Neurology.
[36] Denise C. Park,et al. &bgr;-Amyloid burden in healthy aging: Regional distribution and cognitive consequences , 2012, Neurology.
[37] N. Tzourio-Mazoyer,et al. Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain , 2002, NeuroImage.
[38] Andrew J. Saykin,et al. The pattern of atrophy in familial Alzheimer disease , 2013, Neurology.
[39] J. Morris,et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[40] G L Shulman,et al. INAUGURAL ARTICLE by a Recently Elected Academy Member:A default mode of brain function , 2001 .
[41] A. Dale,et al. Thinning of the cerebral cortex in aging. , 2004, Cerebral cortex.
[42] C. Jack,et al. Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β-amyloidosis. , 2013, JAMA neurology.
[43] C. Jack,et al. Application of the National Institute on Aging–Alzheimer’s Association AD criteria to ADNI , 2013, Neurology.
[44] Kazuyoshi Yajima,et al. Brain FDG PET study of normal aging in Japanese: effect of atrophy correction , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[45] D. T. Vernier,et al. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. , 1990, Journal of lipid research.
[46] Menno P. Witter,et al. Trans-Synaptic Spread of Tau Pathology In Vivo , 2012, PloS one.
[47] E G Tangalos,et al. Prevalence of mild cognitive impairment is higher in men , 2010, Neurology.
[48] S. Thibodeau,et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. , 1996, The New England journal of medicine.
[49] J. Morris,et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup , 2011 .
[50] Pietro Pietrini,et al. Resting state brain glucose metabolism is not reduced in normotensive healthy men during aging, after correction for brain atrophy , 2004, Brain Research Bulletin.
[51] Bedda L. Rosario,et al. Consideration of Optimal Time Window for Pittsburgh Compound B PET Summed Uptake Measurements , 2009, Journal of Nuclear Medicine.
[52] S. DeKosky,et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[53] Cindee M. Madison,et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI , 2011, Neurobiology of Aging.
[54] G. W. Snedecor. STATISTICAL METHODS , 1967 .
[55] C. Rowe,et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging , 2010, Neurobiology of Aging.
[56] M. Weiner,et al. Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden. , 2010, Brain : a journal of neurology.
[57] J B Poline,et al. Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease. , 2007, Brain : a journal of neurology.
[58] Akram Bakkour,et al. The effects of aging and Alzheimer's disease on cerebral cortical anatomy: Specificity and differential relationships with cognition , 2013, NeuroImage.